Four-color flow cytometric analysis of myeloma plasma cells

American Journal of Clinical Pathology

Volumn 126, Issue 6, 2006, Pages 908-915

  Kobayashi, Shoichi ^a   Hyo, Rie ^a   Amitani, Yukiko ^a   Tanaka, Masatsugu ^a   Hashimoto, Chizuko ^a   Sakai, Rika ^a   Tamura, Takeshi ^a   Motomura, Shigeki ^a   Maruta, Atsuo ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

Four color flow cytometric analysis; Immunofixation; Multiple myeloma

Indexed keywords

CD19 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; VINCRISTINE;

ADULT; AGED; ALLOGRAFT; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW; CANCER CYTODIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; FOUR COLOR FLOW CYTOMETRIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOFIXATION; IMMUNOPHENOTYPING; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; STAINING;

EID: 33845451134     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/VWXARAAG9DAPQ31Y     Document Type: Article

References (14)

1. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102:1115-1123.
2. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001;98:29-35.
3. Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric plasma disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood. 2002;100:3095-3100.
4. Owen RG, Johnson RJ, Rawstron AC, et al. Assessment of IgH PCR strategies in multiple myeloma. J Clin Pathol. 1996;49:672-675.
5. Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol. 1997;97:46-55.
6. Sarasquete ME, Garcia-Sanz R, Gonzalez D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90:1365-1372.
7. Billadeau D, Ness BV, Kimlinger T, et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood. 1996;88:289-296.
8. Dahl IM, Rasmussen T, Kauric G, et al. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol. 2002;116:273-277.
9. Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81:2658-2663.
10. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, et al. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol. 2001;14:1052-1058.
11. Ramasamy I, Brisco M, Morley A. Improved PCR method for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell neoplasms. J Clin Pathol. 1992;45:770-775.
12. Pellat-Deceunynck C, Barille S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subser of multiple myeloma. Leukemia. 1998;12:1977-1982.
13. Sahara N, Takeshita A, Shigeno K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol. 2002;117:882-885.
14. Davies FE, Forsyth PD, Rawstron AC, et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol. 2000;112:814-819.